150 related articles for article (PubMed ID: 19591527)
1. Outliers and patients with adverse drug reactions.
Edwards IR
Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
[No Abstract] [Full Text] [Related]
2. Signal selection and follow-up in pharmacovigilance.
Meyboom RH; Lindquist M; Egberts AC; Edwards IR
Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
[TBL] [Abstract][Full Text] [Related]
3. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
4. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
Meier L; Wang EY; Tomes M; Redberg RF
JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
[TBL] [Abstract][Full Text] [Related]
5. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
6. Poisons centres and the reporting of adverse drug events: the case for further development.
Volans GN; Karalliedde L; Wiseman HM
Drug Saf; 2007; 30(3):191-4. PubMed ID: 17343427
[No Abstract] [Full Text] [Related]
7. Novel statistical tools for monitoring the safety of marketed drugs.
Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N
Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548
[TBL] [Abstract][Full Text] [Related]
8. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
Alvarez Y; Hidalgo A; Maignen F; Slattery J
Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
[TBL] [Abstract][Full Text] [Related]
9. Illusions of objectivity and a recommendation for reporting data mining results.
Hauben M; Reich L; Gerrits CM; Younus M
Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
[TBL] [Abstract][Full Text] [Related]
10. [Safety of medicinal products and reporting of adverse drug reactions].
Skibicka I; Maciejczyk A
Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance activities in Nepal.
Palaian S; Mohamed Ibrahim MI; Mishra P; Alam K; Shankar PR; Thapa BB
Drug Saf; 2010 Oct; 33(10):889-90. PubMed ID: 20812773
[No Abstract] [Full Text] [Related]
12. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
13. Statistics: detecting a rare adverse drug reaction using spontaneous reports.
Schroeder DR
Reg Anesth Pain Med; 1998; 23(6 Suppl 2):183-9. PubMed ID: 9845392
[No Abstract] [Full Text] [Related]
14. The utilization and challenges of Japan's MID-NET
Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.
Dijkstra L; Garling M; Foraita R; Pigeot I
Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):396-403. PubMed ID: 32092786
[TBL] [Abstract][Full Text] [Related]
16. Quantitative methods in pharmacovigilance: focus on signal detection.
Hauben M; Zhou X
Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
[TBL] [Abstract][Full Text] [Related]
17. Suspected adverse reactions, 2007.
Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A
Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197
[No Abstract] [Full Text] [Related]
18. [Drug safety: from development to clinical use].
Ovchinnikova EA; Gerasimov VB
Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
[No Abstract] [Full Text] [Related]
19. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
20. Impact of stratification on adverse drug reaction surveillance.
Hopstadius J; Norén GN; Bate A; Edwards IR
Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
